FDA OKs trial of Terumo protocol for polymorphonuclear cells

01/8/2013 | InnovatioNews

The FDA has approved a trial to assess a collection protocol for polymorphonuclear cells using the Spectra Optia platform, according to Terumo BCT. Polymorphonuclear cells from donors could help patients whose immune systems are compromised due to illness or chemotherapy.

View Full Article in:

InnovatioNews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN